Partner With Us NRI

Epigral Ltd share Price Today

Company details

6M Return 43.63%
1Y Return 28.75%
Mkt Cap.(Cr) 5,547.55
Volume 98,029
Div Yield 0.38%
OI Chg %
Volume 98,029

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Specialty chemicals company Meghmani Finechem announced Q1FY24 results:

  • Revenue from operations of Rs 455 crore in Q1FY24 compared to Rs 533 crore in Q1FY23, down 15% YoY
  • EBITDA of Rs 95 crore in Q1FY24 compared to Rs 187 crore in Q1FY23, down 49% YoY
  • PAT of Rs 32 crore in Q1FY24 compared to Rs 108 crore in Q1FY23, down 71% YoY

Commenting on the results Maulik Patel, Chairman and Managing Director, MFL said, “FY24 started with a quarter that witnessed global level slowdown and inventory destocking, impacting the chemical industry both at demand level and also at realization level. MFL too got impacted during the quarter gone by, on account of the drop in realizations. However, MFL achieved volume growth of 11% YoY in Q1FY24; this volume growth is in line with our expansion plans resulting in volume coming from CPVC Resin, Epichlorohydrin, and Hydrogen Peroxide. Revenue contribution from Derivatives and Specialty Chemical stood at 38% compared to 21% for a similar period last year. We estimate this volume growth story will continue further as these new projects will further contribute in FY24.

Considering our long-term vision, we are on schedule for our expansions of CPVC Resin of 45,000 TPA and Chlorotoluene value chain, this will drive volume growth in FY25. Our R&D centre is almost ready; hence we are ready with another strong pillar for our future growth in the Specialty Chemical segment.

We believe that the current scenario is a phase that will pass and the long-term story remains intact. Hence, we are preparing ourselves for long-term growth and we are moving in that direction.

Our board has taken the initiative to rename our company Epigral. This activity is proposed to strengthen our corporate brand in line with our commitment to transform the company as a global multi-product chemical conglomerate and enhance our reputation as an integral partner for esteemed clients and our stakeholders.”



Result PDF

View Other Company Results

Epigral Ltd shares SWOT Analysis

Strengths (7)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Increasing profits every quarter for the past 3 quarters

Weakness (5)

  • MFs decreased their shareholding last quarter
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Degrowth in Revenue and Profit

Opportunity (2)

  • Big Deal (Insider and SAST) buys last month greater than 1% of total shares
  • RSI indicating price strength

Threats (0)

Data not found

Resistance and support

R1 1,368.9
R2 1,402.7
R3 1,422.6


S1 1,315.2
S2 1,295.3
S3 1,261.5
Delivery and volume
Name Category Shares
Ashishbhai Natawarlal Soparkar PROMOTER 11.12%
Patel Natwarlal Meghjibhai PROMOTER 10.05%
Jayantibhai Meghjibhai Patel PROMOTER 8.61%
Rameshbhai Meghjibhai Patel PROMOTER 7.05%
Maulik Jayantibhai Patel PROMOTER 5.29%
Patel Ankit Natwarlal PROMOTER 4.61%
Anandbhai Ishwarbhai Patel PROMOTER 4.37%
Kaushal Ashish Soparkar PROMOTER 4.15%
Taraben Jayantilal Patel PROMOTER 2.43%
Patel Karana Rameshbhai PROMOTER 1.74%
Patel Kalpana Rameshbhai PROMOTER 1.32%
Disha Kevatkumar Vanani PROMOTER 1.17%
Patel Natubhai Meghjibhai (HUF) PROMOTER 1.17%
Bhartiben Natubhai Patel PROMOTER 1.01%
Vaishakhi Dhiren Goyal PROMOTER 1.01%
Chintan Anandbhai Patel PROMOTER 0.98%
Patel Darshan Anandbhai PROMOTER 0.98%
Kruti Adesh Patel PROMOTER 0.88%
Nayanaben A Soparkar PROMOTER 0.81%


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Epigral Ltd Stocks COMPARISON

Financials( in Cr) Epigral Ltd Pidilite Industries Ltd Linde India Ltd SRF Ltd Gujarat Fluorochemicals Ltd
Price 1,335.15 3,109.80 9,262.40 2,402.00 3,266.85
% Change -3.24 1.01 -0.17 0.09 -0.73
Mcap Cr 5,547.55 158,167.23 78,993.45 71,201.29 35,886.35
Revenue TTM Cr 2,188.40 11,799.10 3,135.52 13,138.52 5,684.66
Net Profit TTM Cr 353.29 1,288.87 538.06 1,335.71 1,323.05
PE TTM 28.27 88.74 182.00 53.47 82.56
1 Year Return 28.75 15.75 110.59 2.44 3.94
ROCE 32.02 24.24 16.29 12.52 29.38
ROE 39.36 18.93 14.70 12.25 27.07

Equity Capital: 1,179.10 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 32,317.57 -2,589.17
LAST 3M 111,725.82 -36,230.77
LAST 6M 182,653.52 -16,910.03
LAST 12M 290,144.87 98,834.05
Epigral to conduct AGM

Jun 13, 2024 l BSE Announcement

Epigral Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Jun 12, 2024 l NSE Announcement

Meghmani Finechem Limited - Record Date

Jun 11, 2024 l NSE Announcement

Date Action Type Ratio
Jul 02, 2024 Dividend 50
Jun 20, 2023 Dividend 25
Feb 01, 2023 Dividend 25

Epigral Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Meghmani Finechem Limited was incorporated in 2007 as a subsidiary of Meghmani organics ltd, under the provisions of Companies Act, 1956. The Company at present is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives. The Company is also engaged in Trading of Agrochemical products. The Hon`ble National Company Law Tribunal ("NCLT") Ahmedabad Bench vide its order dated 3 May 2021 (the "Order"), has approved the Scheme of Arrangement ("the Scheme") to demerge the Agrochemicals and Pigments Division of Meghmani Organics Limited ("MOL") along with its investment in Optionally Convertible Redeemable Preference Shares ("OCRPS") of Meghmani Finechem Limited ("MFL") and transferred to the Company as a going concern. The certified true copy of the Order issued by NCLT Ahmedabad Bench on 05th May, 2021 filed with The Ministry of Corporate Affairs (the "MCA") Registrar of Companies ("ROC") Gujarat, Dadra, Nagar and Haveli on 10th May, 2021. The Scheme is effective from 10th May, 2021. By this Meghmani Finechem Limited was demerged from Meghmani Organics in FY 2020-21 to empower the Company grow its Chlor-Alkali business. The demerged Company is now being driven by the second generation of the promoter family that came on the Board of the Company in 2016. The Company`s Chlor-Alkali business was commissioned in 2009, growing from an installed capacity of 1,88,000 TPA in 2015 to 3,15,000 TPA at the close of FY 2020-21. The Company is now among the leading players in India`s chlor alkali industry. The Company grew its business following the commissioning of new plants (Caustic Soda, Hydrogen Peroxide and the 36 MW Captive Power Plant). The timely commissioning of the plants represented the faith of the management in the long-term potential of the sector and country. The Caustic Soda capacity was expanded by 1,27,000 TPA to 2,94,000 TPA and commissioned in June 2020. The Captive Power Plant capacity was increased by 36 MW to 96 MW, commissioned in June 2020. The Company commissioned a 60,000 TPA Hydrogen Peroxide plant in July 2020. The complement of these manufacturing capacities will broadbase the Company`s manufacturing foundation, strengthen integration, moderate the cost structure and provide a platform for value-addition. The payback from these investments is likely to be recovered in 4-5 years, validating the Company`s commitment to profitable growth. During the year under review 2020-21, the Company announced the implementation of a manufacturing facility for Epichlorohydrin (ECH) and Chlorinated Polyvinyl Chloride (CPVC) which are expected to add attractively to the Company`s volumes and profitability across the future. The ECH project will be the first time that the product will be manufactured in India. The 50,000 TPA facility will be based on glycerin feedstock that is obtained from 100% renewable resources, addressing the need for cost-effectiveness and moderated carbon footprint. The project is likely to be commissioned during the first quarter of the next financial year. The CPVC Resin project of 30,000 TPA at a cost of H190 Cr is likely to be commissioned in the second quarter of FY 2022-23.

No Data Found

AGM Date (Month) : Jun
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 543332
Book Closure Date (Month) : Jun
BSE Group : A
ISIN : INE071N01016

FAQ’s on Epigral Ltd Shares

You can buy Epigral Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Epigral Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 14, 2024 03:55 PM the closing price of Epigral Ltd was Rs.1,335.15.

The latest PE ratio of Epigral Ltd as of Jun 14, 2024 03:55 PM is 28.27

The latest PB ratio of Epigral Ltd as of Jun 14, 2024 03:55 PM is 0.23

The 52-week high of Epigral Ltd share price is Rs. 1,443.25 while the 52-week low is Rs. 862.05

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 14, 2024 03:55 PM, the market cap of Epigral Ltd stood at Rs. 5,547.55.

Download App

Download Our App

Play Store App Store
market app